About
Microbot Medical specializes in transformational robotic technologies, focused primarily on the endovascular space. Its LIBERTY Robotic System is the world’s first single-use endovascular robotic system focused on increasing access to robotic technology and revolutionizing the way endovascular procedures are performed.
LIBERTY is the first ever single-use endovascular surgical robotic system designed to streamline endovascular procedures.
In August 2016, U.S.-based StemCells merged with Microbot Medical. In May 2018, the company announced its acquisition of a novel, patent-protected technology from CardioSert. Microbot Medical is now the owner of this technology, including all research and development information, technical know-how, and intellectual property.